SCHEMBL8908414

SCHEMBL8908414

CCCC[Sn](CCCC)(CCCC)c1ccc(C(=O)O)c(N2C(=O)CCC2=O)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PPARA Q07869 2/20 0.34
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 3/20 0.33
TSHR P16473 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA9 Q16790 1/20 0.33
TP53 P04637 1/20 0.33
HPGD P15428 1/20 0.33
PPARG P37231 1/20 0.32
RARB P10826 3/20 0.32
MAPK1 P28482 1/20 0.32
RARA P10276 1/20 0.32
RARG P13631 1/20 0.32
KAT8 Q9H7Z6 2/20 0.32
GABRP O00591 1/20 0.32
GABRD O14764 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4256629 0.80 GAA (0.41) GAAKMT2AKDM4EALDH1A1TSHR
SCHEMBL2723547 0.76 GABRP (0.41) KMT2ASMN1; SMN2PPARAKDM4EALDH1A1
SCHEMBL440026 0.72 ALDH1A1 (0.36) GAAKMT2ASMN1; SMN2KDM4EALDH1A1
SCHEMBL2722616 0.72 PPARA (0.35) PPARAKDM4EALDH1A1PPARGRARB
SCHEMBL3874638 0.71 THRB (0.34) KMT2ASMN1; SMN2HPGD
SCHEMBL27237911 0.71 PPARA (0.49) PPARAPPARGRARBRARARARG
SCHEMBL6887707 0.70 CA12 (0.48) GAAKMT2AALDH1A1TSHRCA12
SCHEMBL317703 0.69 KEAP1 (0.43) GAAKMT2AKDM4EALDH1A1TSHR
SCHEMBL31653832 0.69 KEAP1 (0.43) GAAKMT2AKDM4EALDH1A1TSHR
SCHEMBL317626 0.69 CA12 (0.42) GAAKMT2AKDM4ECA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11911488-B2 Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy THE JOHNS HOPKINS UNIVERSTY (US) 2024-02-27 US disclosed
US-20200360542-A1 SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY THE JOHNS HOPKINS UNIVERSTY 2020-11-19 US disclosed
US-10736974-B2 Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy THE JOHNS HOPKINS UNIVERSITY (US) 2020-08-11 US disclosed
US-10512700-B2 Radiohalide-labeled targeted diagnostics and therapeutics MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2019-12-24 US disclosed
US-20170333576-A1 NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY THE JOHNS HOPKINS UNIVERSITY (US) 2017-11-23 US disclosed
US-20170266327-A1 RADIOHALIDE-LABELED TARGETED DIAGNOSTICS AND THERAPEUTICS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-09-21 US disclosed
US-5609848-A Radiohalogenated small molecules for protein labeling NEORX CORPORATION (US) 1997-03-11 US disclosed
US-5213787-A RADIOHALOGENATED SMALL MOLECULES FOR PROTEIN LABELING NEORX CORPORATION (US) 1993-05-25 US disclosed
US-5102651-A PROCESS FOR ISOLATION AND RADIOLABELING OF PHARMACEUTICALS WITH ISOTOPES OF ASTATINE NEORX CORPORATION (US) 1992-04-07 US disclosed
US-5045303-A Radiohalogenated small molecules for protein labeling NEORX CORPORATION (US) 1991-09-03 US disclosed
WO-1991009626-A1 PROCESS FOR ISOLATION AND RADIOLABELING OF PHARMACEUTICALS WITH ISOTOPES OF ASTATINE NEORX CORPORATION (US) 1991-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200360542-A1 SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY FOLH1, PSMA3, PSMA7 GAA 402/4885KMT2A 3647/4885SMN1; SMN2 3838/4885
US-11911488-B2 Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy FOLH1, PSMA3, PSMA7 GAA 402/4885KMT2A 3647/4885SMN1; SMN2 3838/4885
US-20170333576-A1 NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY FOLH1, PSMA3, PSMA7 GAA 605/4885KMT2A 3946/4885SMN1; SMN2 4270/4885
US-20170266327-A1 RADIOHALIDE-LABELED TARGETED DIAGNOSTICS AND THERAPEUTICS PARP11, PARP1, PARP12 GAA 1485/4885KMT2A 917/4885SMN1; SMN2 3675/4885
US-10512700-B2 Radiohalide-labeled targeted diagnostics and therapeutics PARP11, PARP1, PARP12 GAA 1485/4885KMT2A 917/4885SMN1; SMN2 3675/4885
US-10736974-B2 Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy FOLH1, PSMA3, PSMA7 GAA 402/4885KMT2A 3647/4885SMN1; SMN2 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.